Announcement PDF Acrux Limited (ACR:ASX) | ACN 082 001 152 103-113 Stanley St, West Melbourne VIC, 3003 Australia +61 3 8379 0100 | info@acrux.com.au Acrux Limited (ACR:ASX) ASX Announcement 6 August 2026 Investor Presentation – Bioshares Biotech Summit Today our CEO and Managing Director, John Warmbrunn, is presenting at Bioshare’s 20th Biotech Summit. A copy of this Investor Presentation which has a clear focus on Female Testosterone accompanies this release. Authorised for release by the Chair of Board of Acrux Limited. For more information, please contact: John Warmbrunn Acrux Limited CEO & Managing Director P: + 61 3 8379 0100 E: john.warmbrunn@acrux.com.au About Acrux: Acrux (ASX: ACR) has spent 25 years building deep expertise in transdermal and topical drug delivery. We're now executing a focused strategy to address women’s health through hormone replacement therapies. This is supported by a diversified portfolio of topical generic pharmaceuticals, already commercialised in the US market. Click here to sign up to our InvestorHub and keep up to date with company news and latest developments or further information on Acrux Limited, visit www.acrux.com.au END. Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Healthspan John Warmbrunn CEO & Managing Director Acrux Ltd August 2026 2 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Disclaimer This presentation contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are reasonably expected to take place. Actual results could differ materially depending on factors such as the availability of resources, the results of non-clinical and clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of our Company, the Directors and our management. We cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur and investors are cautioned not to place undue reliance on these forward- looking statements. We have no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation, except where required by law and under our continuous disclosure obligations. These forward-looking statements are subject to various risk factors that could cause our actual results to differ materially from the results expressed or anticipated in these statements. 3 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 LOW LIBIDO and HEALTHSPAN Illustrative diagram only 4 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 What is Hypoactive Sexual Desire Disorder (HSDD)? ~4.9m menopausal women in the US affected ~10% of all adult women impacted Commonly expressed as low or absent sexual desire and/or response to stimulation Other symptoms include: Low self- esteem Reduced energy Social conflict Depression Anxiety References: • Islam, RM, Bell, RJ, Green, S, Page, MJ, Davis, SR, (2019). Safety and efficacy of testosterone for women: a systematicreview and meta-analysis of randomisedcontrolled trial data. The Lancet Diabetes & Endocrinology. Vol. 7(10), 754–766. • Ronghe V, Pannase K, Gomase KP, Mahakalkar MG, (2023) UnderstandingHypoactive Sexual Desire Disorder(HSDD) in Women: Etiology, Diagnosis,nd Treatment. Cureus. Vol. 15(11) • Parish,SJ, Kling, JM, (2023). Testosteroneuse for hypoactive sexual desiredisorder in postmenopausal women. Menopause. Vol. 30(7) 781-783 • Shifren,JL, Monz,BU, Russo, PA, Segreti,A, & Johannes,CB. (2008). Sexual problems and distress in United States women: prevalenceand correlates. Obstetricsand gynecology,112(5), 970–978 5 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 HSDD impacts more than desire SEXUAL HEALTH Desire – Intimacy - Satisfaction Addressing HSDD can help women reclaim their well-being - inside and out It touches every part of a women’s well being SELF CONFIDENCE Body image – Self esteem – Feeling like yourself RELATIONSHIP HEALTH Connection – Communication - Closeness EMMOTIONAL WELL- BEING Mood – Stress – Mental wellness QUALITY OF LIFE Fulfilment – Happiness – Life satisfaction Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Professor Susan R Davis AO, MBBS FRACP PhD FAHMS • Head of the Monash Women’s Health Research program. • Fellow and council member of the Australian Academy of Health and Medical Sciences. • Advisor to the NHS Menopause Improvement Program Steering Committee. • Author of the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women. ^ * Acrux Testosteroneis not yet registered for this indication. # MDTS – Metered Dose Transdermal System ^ Davis, SR, Baber, R, Panay, N, Bitzer,J, Perez, SC,Islam, RM, Kaunitz, AM, KingsbergSA, LambrinoudakiI, Liu J, Parish SJ, PinkertonJ, Rymer J, Simon JA, Vignozzi,L, WiermanME, (2019). Global ConsensusPositionStatement onthe Use of TestosteroneTherapy for Women. The Journalof ClinicalEndocrinology & Metabolism. Vol 104(10), pp. 4660-4666. Testosterone is not simply a male hormone but is also an important hormone in women. Low sexual desire is the most prevalent sexual concern amongst women. When sufficient to cause personal distress women are considered as having hypoactive sexual desire dysfunction or HSDD. There is irrefutable evidence that testosterone therapy in doses that result in blood levels within the physiological range for premenopausal women improves sexual desire, arousal, orgasm and sexual self-image and reduces personal distress in postmenopausal women with HSDD. Acrux’s Testosterone* MDTS# has the advantages of acting as a "patchless" patch with good pharmacokinetic evidence of absorption 7 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Significant Global Market Opportunity 18-44 years $7.91 45-65 years $8.85 65+ years $4.54 Estimated US & EU HSDD Market Potential p.a. (US$B) US$21.3B Total US HSDD market potential p.a HSDD postmenopausal women 45% HSDD premenopausal women 9% Post-cancer treatment sexual dysfunction 8% Premature menopause 6% IVF / ovarian priming 4% Alzheimer's / cognitive decline 28% Potential Global Population for Female Testosterone* ~120m Women globally estimated to have HSDD by 2030 *There is no known publishedmarket reportthat segmentsthe testosterone marketexclusively for women by indication/population. The percentagesshown are derived estimatesconstructedfrom information, real-worldprescribingpatterns, epidemiology, and othertherapy information. Estimates are intended for strategic and illustrative purposesand are not sourced from a single proprietarymarket report." Assumptions: 12.3% 45-65y, 8.9% 18-44 y and 7.4% >65 y have HSDD; Cost of annualtreatment= $USD 300 per month;40% may women respondto treatment/clinically meaningful improvements; and 75% women would speak to doctor & 82% of these initiate discussionwith healthcareprovider. References: Hill K., (1996) The demographyof menopause, Maturitas23:113-127. Parish SJ et al, (2021) InternationalSociety for the Study of Women’sSexual Health ClinicalPractice Guidelinefor the Use of SystemicTestosterone for Hypoactive Sexual Desire Disorder in Women J Sex Med 18:849-867. ~60m women in the US estimated to be affected by menopause ~4.9m menopausal women estimated with HSDD ~2m US women are estimated to use off-label testosterone products for HSDD Acrux Ltd (ASX:ACR) Female Testosterone MDTS Helping millions of women with Hypoactive Sexual Desire Disorder (HSDD) Bioshares Biotech Summit | 6 August 2026 9 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Testosterone: A Transformative Opportunity in Women's Health HSDD is the primary clinical application for testosterone therapy in women, serving as the foundation of treatment. • Sexual Health Spectrum Testosterone influences multiple aspects of female sexual function including FSAD and orgasmic disorders beyond HSDD. • Cognition and Memory Emerging research links testosterone to cognitive performance and healthy aging in women. • Bone and Musculoskeletal Health Testosterone supports skeletal integrity, muscle strength, and physical well-being in women. Core Indication HSDD Potential beyond HSDD 01 Acrux Ltd (ASX:ACR) Female Testosterone MDTS Blockbuster potential 11 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Acrux History Innovative Skin Delivery Technology Topical Generics 1998: Acrux incorporated to commercialise unique drug delivery technology invented at Monash University 2001: First US patent granted 2004: ASX listing 2011: Axiron® launched by Eli Lilly 2022: Lidocaine 2.5% and Prilocaine 2.5% Cream) launched in USA 2024: Launch Nitroglycerine 0.4%, Ointment 2003: Recuvyra® Veterinary product licensed to Elanco globally 2007: Evamist® licensed to KV Pharmaceutical in US 2016: Lenzetto® launched in Europe by Gedeon Richter 2024: Launch Dapsone 5%, Gel 2025: Launch Dapsone 7.5%, Gel MALE TESTOSTERONE ESTRADIOL 12 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Acrux Proven MDTS Technology Proprietary MDTS (Metered Dose Transdermal System) Applicator Delivers a controlled spray of Female Testosterone through the skin Patchless Patch forms an invisible reservoir within the skin No alternative competitor Applicator launched in 18 years Lenzetto® and Evamist® delivery technology ensures high scalability once in market. 13 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Female Testosterone Awareness Female Testosterone is gaining significant mainstream patient population awareness and traction across key global markets. 14 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Global Positioning of Testosterone Therapy for Women Historical Barriers New Global Pathway FDA“Black box" warnings: On hormone therapy products for over 20 years, its strongest caution creating a significant barrier for providers and patients. Off-Label Prescribing: Testosterone therapy for women is often based on male formulations and lack standardised dosing. Safety & Efficacy : Inconsistent treatment outcomes and dosing raised risks and patient safety issues. Regulatory & Research Gaps: Absence of female-specific products and regulatory clarity hindered pharmaceutical innovation. First evidence-based guidelines: For testosterone therapy in women worldwide from Global Consensus Position Statement (GCS) in 2019. Removal of Black box warnings: FDA with renewed focus on menopause and hormone-therapy policy, seeks to encourage treatments. GCS noted an unmet medical need for a testosterone transdermal product formulated for female clinical use. Female Testosterone MDTS® (4.5 mg per spray) has been shown to achieve this clinically. 02 Acrux Ltd (ASX:ACR) Phase III Study Development roadmap in place 16 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Clear Phase II Results • Mean number of satisfactory sexual events increased compared to placebo at weeks 4, 8, 12 and 16 for all of the testosterone groups. • Statistically significant increase in the primary endpoint in the 1 × 90 µL testosterone group in the intent-to-treat (ITT) population, with a mean increase of 2.00 satisfactory sexual events at week 16, compared to a mean increase of 0.53 events in the placebo group (the mean baseline frequency in each of these groups was 1.3-1.4). 0.0 0.5 1.0 1.5 2.0 2.5 3.0 week 4 week 8 week 12 week 16 Number of Satisfactory Sexual Events: Change from Baseline placebo 1 x 56 uL 1 x 90 uL 2 x 90uL 17 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Phase III Pivotal Clinical Trial Design - A Critical Next Step Study Design Title A Phase III, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Testosterone Transdermal Spray for the Treatment of Sexual Dysfunction (Hypoactive Sexual Desire Disorder) in Postmenopausal Women Co-primary Endpoints • Sexually Satisfying Events and Sexual Desire Score • [Time Frame: baseline through 24 weeks] Secondary Endpoint • Female Sexual Distress Score • [Time Frame: baseline through 24 weeks] USA Australia FDA Pre-IND recent feedback FDA Post end-of-Phase-II response received July-2026 TGA recent feedback TGA meeting held December-2025 18 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Lifecycle Strategy for Further Development New improved MDTS applicator with patent protection MDTS Companion Smartphone App Expand proposed indication/ population to include: • Female sexual interest/arousal disorder (FSIAD) • Female sexual arousal disorder (FSAD) • Women with premature menopause • For women post- chemotherapy/ radiotherapy • Potential as part of IVF treatment • Cognitive symptoms 03 Acrux Ltd (ASX:ACR) Development Roadmap Close to market - Clear regulatory pathway 20 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Co-development Roadmap • Focus is on progressing potential co-development partnerships in the near-term to de-risk the clinical trial process and expedite market launch. • Well positioned with existing distribution and product agreements in place with potential co-development partners. • Strong interest from women’s health specialist pharma • Proactively work with its co- development partner to finalise the Phase III trial design and manufacturing protocols. 2026 2027 2028 2029 2030 Co-development Partnering CRO Contract Manufacturing Phase III Trials & Trial supply Dossier to US FDA Submission and Product Launch Multiple near-term and medium-term milestones will ensure strong investor engagement and catalysts through to product launch in the US in 2019 Acrux Ltd (ASX:ACR) Female Testosterone MDTS Helping millions of women with Hypoactive Sexual Desire Disorder (HSDD) Bioshares Biotech Summit | 6 August 2026 22 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Phase III stage asset. Significant, fast-growing market. Early mover advantage. Patient preferred application. Co-development pathway. Female Testosterone MDTS catalyses Acrux’s investment proposition Helping millions of women with Hypoactive Sexual Desire Disorder (HSDD) 23 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Pooled Development Fund Purpose • Pooled Development Fund Act 1992 was established by the Federal Government • Increase the supply of capital to Australian small and medium-sized enterprises to enable those businesses to grow and develop their own markets, creating industry and jobs for Australia Benefits  Capital gains made by PDF shareholders are not taxable  Shareholders can elect to treat dividends paid by a PDF as tax free  Capital losses on the sale of PDF’s are not deductible 24 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026 Successful development and FDA registration of topical pharmaceuticals generates core Acrux income • Nitroglycerin 0.4% ointment launched. • Dapsone 5.0% gel launched. • Dapsone 7.5% gel launched. • Evamist® royalties continue. • Ophthalmic, Otic, and Topical. 0 0.5 1 1.5 2 2.5 3 3.5 4 FY25 FY26 License revenues from Generic portfolio Q1 Q2 Q3 Q4 FDA registered products commercialised in the US Geographic expansion of FDA registered products Further Female HRT licensing expansion Unprofitable assets removed from portfolio Realisation of generic pipeline via partnerships Includes $1.35M upfront payment for Lenzetto® in Australia Acrux Ltd (ASX:ACR) THANKYOU Questions Bioshares Biotech Summit | 6 August 2026